> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Perspectum’s Liver Cancer Support Tool Cleared
- URL: https://www.fdaweb.com/perspectums-liver-cancer-support-tool-cleared/
- Published: 2021-01-28T12:00:00.000Z
- Updated: 2026-09-14T16:44:36.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5148551

FDA has cleared a Perspectum 510(k) for Hepatica, a precision oncology decision support tool for liver cancer. The device a quantitative multiparametric MRI to provide a liver health assessment based on artificial intelligence (AI)-driven liver segmentation together with proprietary biomarkers for hepatic fibro-inflammation and fat, according to the company. “Using AI to delineate the liver and calculate regional volumes saves over 20 minutes of pre-operative radiology time per case,” it says.

The clearance was based on data from a UK-based study of 143 surgical candidates which showed that by combining estimated future liver remnant with an assessment of underlying fibro-inflammation, Hepatica could effectively identify patients at risk of poor outcomes from surgery and a longer stay in hospital, Perspectum says. This information, it adds, helps tumor boards and multidisciplinary teams make more informed pre-operative decisions to improve post-operative outcomes for patients.